GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NextGen Biomed Ltd (XTAE:NXGN) » Definitions » PS Ratio

NextGen Biomed (XTAE:NXGN) PS Ratio : (As of Jun. 07, 2024)


View and export this data going back to 2000. Start your Free Trial

What is NextGen Biomed PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, NextGen Biomed's share price is ₪1.018. NextGen Biomed's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was ₪0.00. Hence, NextGen Biomed's PS Ratio for today is .

The historical rank and industry rank for NextGen Biomed's PS Ratio or its related term are showing as below:

XTAE:NXGN's PS Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 3.21
* Ranked among companies with meaningful PS Ratio only.

NextGen Biomed's Revenue per Sharefor the six months ended in Jun. 2023 was ₪0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was ₪0.00.

Back to Basics: PS Ratio


NextGen Biomed PS Ratio Historical Data

The historical data trend for NextGen Biomed's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextGen Biomed PS Ratio Chart

NextGen Biomed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PS Ratio
Get a 7-Day Free Trial Premium Member Only - - - - -

NextGen Biomed Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NextGen Biomed's PS Ratio

For the Medical Instruments & Supplies subindustry, NextGen Biomed's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextGen Biomed's PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NextGen Biomed's PS Ratio distribution charts can be found below:

* The bar in red indicates where NextGen Biomed's PS Ratio falls into.



NextGen Biomed PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

NextGen Biomed's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.018/0
=

NextGen Biomed's Share Price of today is ₪1.018.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NextGen Biomed's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was ₪0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


NextGen Biomed  (XTAE:NXGN) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


NextGen Biomed PS Ratio Related Terms

Thank you for viewing the detailed overview of NextGen Biomed's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NextGen Biomed (XTAE:NXGN) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Round Tower 22nd Floor, Tel Aviv, ISR, 6701101
NextGen Biomed Ltd is pharmaceutical company. It manufactures medical instruments. Its products include pain-free auto-injectors, lancet devices and personal use pain alleviators. It develops and markets medical equipments. Its product line include DPS-101, which is used for treatment for psoriasis. Its other product line include DPS-101 phase II/III is in clinical trial.